KUALA LUMPUR (Sept 28): Bintai Kinden Corp Bhd sai
Post# of 36537
(Total Views: 304)
Posted On: 09/28/2020 12:28:07 PM
KUALA LUMPUR (Sept 28): Bintai Kinden Corp Bhd said it today entered into a memorandum of understanding (MOU) with Institut Jantung Negara Sdn Bhd (IJN) to explore a possible collaboration in the commercial development of Covid-19 vaccine in Malaysia based on an existing partnership between Bintai Kinden and US-based Generex Biotechnology Corp.
In a statement to Bursa Malaysia today, Bintai Kinden said it is partnering Generex to commercialise the Ii-Key-SARS-CoV-2 coronavirus vaccine in Malaysia.
IJN is also known as the National Heart Institute, which specialises in cardiovascular and thoracic medicine, according to its website.
In a statement to Bursa Malaysia today, Bintai Kinden said it is partnering Generex to commercialise the Ii-Key-SARS-CoV-2 coronavirus vaccine in Malaysia.
IJN is also known as the National Heart Institute, which specialises in cardiovascular and thoracic medicine, according to its website.
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼